PriceTargets.com logo

AdaptHealth - AHCO Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $11.67
  • Forecasted Upside: 13.49%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$10.28 As of 12/20/2024 06:51 PM ET
▲ +0.59 (6.09%)

This chart shows the closing price for AHCO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AdaptHealth Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AHCO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AHCO

Analyst Price Target is $11.67
▲ +13.49% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for AdaptHealth in the last 3 months. The average price target is $11.67, with a high forecast of $14.00 and a low forecast of $8.00. The average price target represents a 13.49% upside from the last price of $10.28.

This chart shows the closing price for AHCO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 investment analysts is to moderate buy stock in AdaptHealth. This rating has held steady since October 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/19/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$13.00 ➝ $11.00
11/15/2024Truist FinancialLower TargetBuy ➝ Buy$13.00 ➝ $12.00
11/6/2024UBS GroupLower TargetBuy ➝ Buy$13.00 ➝ $12.00
11/6/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$14.00 ➝ $13.00
11/6/2024Robert W. BairdLower TargetOutperform ➝ Outperform$16.00 ➝ $14.00
8/12/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$13.00 ➝ $13.00
5/15/2024Truist FinancialReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
3/4/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$13.00
2/28/2024UBS GroupBoost TargetBuy ➝ Buy$9.00 ➝ $13.00
2/28/2024Truist FinancialBoost TargetBuy ➝ Buy$11.00 ➝ $13.00
1/29/2024UBS GroupLower TargetBuy ➝ Buy$10.00 ➝ $9.00
1/8/2024Jefferies Financial GroupDowngradeBuy ➝ Hold$14.50 ➝ $8.00
11/8/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$18.00 ➝ $13.00
11/8/2023Truist FinancialLower TargetBuy ➝ Buy$14.00 ➝ $11.00
11/8/2023Bank of AmericaDowngradeNeutral ➝ Underperform$9.50 ➝ $6.50
10/11/2023Truist FinancialLower TargetBuy ➝ Buy$18.00 ➝ $14.00
9/22/2023Bank of AmericaLower TargetNeutral ➝ Neutral$13.00 ➝ $11.00
7/13/2023Robert W. BairdBoost Target$20.00 ➝ $21.00
5/11/2023Royal Bank of CanadaLower Target$24.00 ➝ $18.00
5/10/2023Robert W. BairdLower Target$23.00 ➝ $20.00
5/10/2023Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$28.00 ➝ $11.30
5/9/2023Stifel NicolausDowngradeBuy ➝ Hold$18.00 ➝ $11.00
5/9/2023Bank of AmericaDowngradeBuy ➝ Neutral$21.00 ➝ $12.00
4/13/2023Truist FinancialLower TargetBuy$20.00 ➝ $17.00
3/1/2023SVB SecuritiesLower Target$30.00 ➝ $23.00
3/1/2023Truist FinancialLower Target$28.00 ➝ $20.00
3/1/2023Robert W. BairdLower TargetOutperform$31.00 ➝ $23.00
11/10/2022Leerink PartnersBoost TargetOutperform$29.00 ➝ $30.00
11/9/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$26.00 ➝ $28.00
9/20/2022Deutsche Bank AktiengesellschaftBoost TargetBuy$26.00 ➝ $28.00
9/19/2022Truist FinancialBoost TargetBuy$26.00 ➝ $28.00
8/10/2022Deutsche Bank AktiengesellschaftBoost Target$22.00 ➝ $26.00
8/10/2022Leerink PartnersBoost TargetOutperform ➝ Outperform$24.00 ➝ $29.00
7/14/2022Truist FinancialBoost TargetBuy$20.00 ➝ $24.00
5/12/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$29.00 ➝ $26.00
5/11/2022Deutsche Bank AktiengesellschaftLower Target$28.00 ➝ $22.00
3/8/2022Royal Bank of CanadaLower TargetOutperform$31.00 ➝ $26.00
3/2/2022Leerink PartnersLower TargetOutperform$32.00 ➝ $24.00
2/25/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$44.00 ➝ $29.00
2/25/2022Truist FinancialLower Target$30.00 ➝ $20.00
2/25/2022Deutsche Bank AktiengesellschaftLower Target$34.00 ➝ $28.00
2/25/2022Robert W. BairdLower Target$34.00 ➝ $26.00
2/18/2022Leerink PartnersLower TargetOutperform$35.00 ➝ $32.00
11/5/2021Leerink PartnersBoost TargetOutperform$30.00 ➝ $35.00
10/13/2021Truist FinancialLower TargetBuy$40.00 ➝ $30.00
9/27/2021Leerink PartnersInitiated CoverageOutperform$30.00
7/14/2021Robert W. BairdUpgradeNeutral ➝ Outperform$30.00 ➝ $36.00
5/7/2021Deutsche Bank AktiengesellschaftLower TargetHold ➝ Sell$47.00 ➝ $40.00
4/19/2021Robert W. BairdReiterated RatingOutperform ➝ Neutral$35.00
4/13/2021Robert W. BairdDowngradeOutperform ➝ Neutral$35.00
4/12/2021Robert W. BairdBoost TargetPositive ➝ Outperform$47.00 ➝ $49.00
3/18/2021Truist FinancialInitiated CoverageBuy$48.00
1/26/2021Bank of AmericaInitiated CoverageBuy$46.00
12/10/2020UBS GroupInitiated CoverageBuy$49.00
12/4/2020Deutsche Bank AktiengesellschaftBoost TargetBuy$36.00 ➝ $47.00
12/2/2020Leerink PartnersBoost TargetOutperform$32.50 ➝ $39.50
12/2/2020Royal Bank of CanadaBoost TargetPositive ➝ Outperform$36.00 ➝ $50.00
11/17/2020Deutsche Bank AktiengesellschaftBoost TargetBuy$26.00 ➝ $36.00
11/16/2020Robert W. BairdInitiated CoverageOutperform$35.00
11/5/2020Leerink PartnersBoost TargetOutperform$23.50 ➝ $32.50
8/11/2020Royal Bank of CanadaBoost TargetOutperform$24.00 ➝ $33.00
8/6/2020Deutsche Bank AktiengesellschaftBoost Target$10.00 ➝ $26.00
7/1/2020Leerink PartnersInitiated CoverageOutperform$21.00
6/9/2020Royal Bank of CanadaInitiated CoverageOutperform$24.00
5/27/2020Stifel NicolausBoost TargetBuy$18.00 ➝ $20.00
2/28/2020Deutsche Bank AktiengesellschaftBoost TargetBuy$12.00 ➝ $19.00
2/26/2020Stifel NicolausBoost TargetBuy$17.00 ➝ $18.00
1/30/2020Stifel NicolausInitiated CoverageBuy$17.00
1/7/2020Jefferies Financial GroupInitiated CoverageBuy$15.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.10 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 13 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 6 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 11 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 9 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 10 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 7 very positive mentions
  • 16 positive mentions
  • 8 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 13 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 13 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

AdaptHealth logo
AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs. It also offers wheelchairs, hospital beds, oxygen concentrators, CPAP masks and related supplies, wound care supplies, diabetes management supplies, wheelchair cushion accessories, orthopedic bracing, breast pumps and supplies, walkers, commodes and canes, and nutritional and incontinence supplies. The company services beneficiaries of Medicare, Medicaid, and commercial insurance payors. The company is headquartered in Plymouth Meeting, Pennsylvania.
Read More

Today's Range

Now: $10.28
Low: $9.56
High: $10.48

50 Day Range

MA: $10.12
Low: $9.18
High: $11.00

52 Week Range

Now: $10.28
Low: $6.46
High: $11.90

Volume

11,860,807 shs

Average Volume

1,111,880 shs

Market Capitalization

$1.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Frequently Asked Questions

What sell-side analysts currently cover shares of AdaptHealth?

The following equities research analysts have issued reports on AdaptHealth in the last twelve months: Canaccord Genuity Group Inc., Jefferies Financial Group Inc., Robert W. Baird, Royal Bank of Canada, Truist Financial Co., and UBS Group AG.
View the latest analyst ratings for AHCO.

What is the current price target for AdaptHealth?

0 Wall Street analysts have set twelve-month price targets for AdaptHealth in the last year. Their average twelve-month price target is $11.67, suggesting a possible upside of 13.5%. Robert W. Baird has the highest price target set, predicting AHCO will reach $14.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $8.00 for AdaptHealth in the next year.
View the latest price targets for AHCO.

What is the current consensus analyst rating for AdaptHealth?

AdaptHealth currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for AHCO.

What other companies compete with AdaptHealth?

Other companies that are similar to AdaptHealth include Guardant Health, Option Care Health, Sotera Health, Veracyte and BrightSpring Health Services. Learn More about companies similar to AdaptHealth.

How do I contact AdaptHealth's investor relations team?

AdaptHealth's physical mailing address is 220 West Germantown Pike Suite 250, Plymouth Meeting PA, 19462. The company's listed phone number is (610) 424-4515 and its investor relations email address is [email protected]. The official website for AdaptHealth is www.adapthealth.com. Learn More about contacing AdaptHealth investor relations.